The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide (“AZD9291”) or a pharmaceutically acceptable salt thereof, wherein such compositions comprise a certain amount of microcrystalline cellulose and at least one other pharmaceutical diluent.本發明係關於適於經口投與之醫藥組合物，且更特別關於含有N-(2-{2-二甲基胺基乙基-甲基胺基}-4-甲氧基-5-{[4-(1-甲基吲哚-3-基)嘧啶-2-基]胺基}苯基)丙-2-烯醯胺(「AZD9291」)或其醫藥上可接受之鹽之醫藥組合物(包括醫藥錠劑組合物)，其中該等組合物包含一定量的微晶纖維素及至少一種其他醫藥稀釋劑。
